J&J Jumps On RNA-Based Small Molecules Train In Pact With Remix

 
• By Alaric DeArment

Deal Snapshot: The deal, with an upfront payment of $45m, is the latest of several involving large biopharma companies and smaller firms focused on small molecule drugs based on RNA biology.

Single strand ribonucleic acid, RNA
Remix and J&J announced a deal to develop small molecule drugs based on RNA biology • Source: Shutterstock

Who: Johnson & Johnson / Remix Therapeutics

What: The two companies signed a deal to develop small molecule drugs that modulate RNA processing using Remix’s REMaster drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business